Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free TVTX Stock Alerts

Travere Therapeutics (TVTX) Financials

Travere Therapeutics logo
$66.54 -0.69 (-1.03%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Travere Therapeutics

Annual Income Statements for Travere Therapeutics

This table shows Travere Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 117 -48 -60 -103 -146 -169 -180 -278 -111 -322 -26
Consolidated Net Income / (Loss)		 117 -48 -60 -103 -146 -169 -180 -278 -111 -322 -26
Net Income / (Loss) Continuing Operations		 117 -48 -60 -103 -146 -169 -217 -331 -376 -321 -50
Total Pre-Tax Income 		105 -58 -58 -102 -146 -189 -217 -331 -376 -321 -49
Total Operating Income		 -51 -58 -54 -80 -137 -176 -199 -320 -388 -324 -63
Total Gross Profit		 98 129 151 159 170 192 128 105 134 225 480
Total Revenue		 100 134 155 164 175 198 132 109 145 233 491
Operating Revenue		 100 134 155 164 175 198 132 109 145 233 491
Total Cost of Revenue		 2.19 4.55 3.61 5.53 5.23 6.13 3.82 4.42 11 7.74 10
Operating Cost of Revenue		 2.19 4.55 3.61 5.53 5.23 6.13 3.82 4.42 11 7.74 10
Total Operating Expenses		 148 187 205 239 307 368 327 425 522 549 543
Selling, General & Admin Expense		 80 92 101 104 129 136 126 198 266 264 337
Research & Development Expense		 50 71 78 124 141 229 201 227 245 283 206
Restructuring Charge		 0.00 0.89 3.61 -0.24 - - 0.00 0.00 11 2.44 0.00
Total Other Income / (Expense), net		 156 0.67 -4.57 -22 -9.09 -13 -17 -11 12 3.32 14
Interest Expense		 4.15 0.73 4.42 27 - 0.00 0.00 19 11 11 11
Interest & Investment Income		 -7.75 - 3.23 5.50 -8.77 -14 -18 6.28 22 18 13
Other Income / (Expense), net		 168 1.39 -3.38 -0.47 -0.31 1.42 0.23 0.97 1.59 -3.32 12
Income Tax Expense		 -12 -9.68 1.37 0.81 -0.02 -19 0.41 0.31 0.22 0.12 0.99
Net Income / (Loss) Discontinued Operations		 - - - - - - 37 53 265 -0.92 25
Basic Earnings per Share		 $3.49 ($1.29) ($1.54) ($2.54) ($3.46) ($3.56) ($3.01) ($4.37) ($1.50) ($4.08) ($0.29)
Weighted Average Basic Shares Outstanding		 33.56M 37.00M 38.77M 40.43M 42.34M 47.54M 59.83M 63.76M 74.27M 78.89M 89.21M
Diluted Earnings per Share		 $3.17 ($1.29) ($1.54) ($2.54) ($3.46) ($3.56) ($3.01) ($4.37) ($1.50) ($4.08) ($0.29)
Weighted Average Diluted Shares Outstanding		 37.58M 38.29M 38.77M 40.43M 42.34M 47.54M 59.83M 63.76M 74.27M 78.89M 89.21M
Weighted Average Basic & Diluted Shares Outstanding		 33.60M 37.10M 38.77M 40.43M 42.34M 47.54M 63.21M 64.74M 76.10M 88.74M 92.24M

Quarterly Income Statements for Travere Therapeutics

This table shows Travere Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -90 -136 -70 -55 -61 -41 -13 26 2.73 -37 -35
Consolidated Net Income / (Loss)		 -90 -136 -70 -55 -60 -41 -13 26 2.73 -37 -35
Net Income / (Loss) Continuing Operations		 -89 -136 -70 -55 -60 -41 -13 26 -22 -37 -35
Total Pre-Tax Income 		-89 -136 -70 -55 -60 -41 -13 26 -21 -37 -35
Total Operating Income		 -94 -139 -68 -56 -61 -43 -13 25 -32 -37 3.95
Total Gross Profit		 40 40 52 61 72 77 113 163 127 125 167
Total Revenue		 45 41 54 63 75 82 114 165 130 127 170
Operating Revenue		 45 41 54 63 75 82 114 165 130 127 170
Total Cost of Revenue		 4.56 1.50 2.06 1.63 2.55 4.68 1.52 1.59 2.55 1.95 2.17
Operating Cost of Revenue		 4.56 1.50 2.06 1.63 2.55 4.68 1.52 1.59 2.55 1.95 2.17
Total Operating Expenses		 135 179 120 117 133 120 126 138 160 162 163
Selling, General & Admin Expense		 64 64 65 66 70 60 63 86 102 80 96
Research & Development Expense		 60 115 54 52 62 47 49 52 58 57 60
Other Operating Expenses / (Income)		 - - - - - 12 14 - - 25 7.06
Total Other Income / (Expense), net		 5.71 3.47 -1.86 1.31 0.40 1.49 -0.09 0.78 11 0.19 -39
Interest Expense		 - 2.80 2.79 2.78 - 2.86 2.85 2.75 2.29 2.30 42
Interest & Investment Income		 10 6.03 4.42 3.57 6.60 3.80 3.29 3.05 2.59 2.58 3.36
Other Income / (Expense), net		 1.37 0.24 -3.50 0.52 -0.58 0.55 -0.53 0.49 11 -0.09 -0.17
Income Tax Expense		 0.07 0.19 0.09 -0.08 -0.07 0.04 0.02 0.01 0.92 -0.12 -0.20
Net Income / (Loss) Discontinued Operations		 -1.58 -0.10 -0.76 -0.06 0.00 0.00 0.00 0.00 25 -0.50 0.00
Basic Earnings per Share		 ($1.07) ($1.76) ($0.91) ($0.70) ($0.71) ($0.47) ($0.14) $0.29 $0.03 ($0.40) ($0.37)
Weighted Average Basic Shares Outstanding		 74.27M 77.14M 77.50M 77.78M 78.89M 88.36M 88.95M 89.23M 89.21M 91.87M 93.48M
Diluted Earnings per Share		 ($1.07) ($1.76) ($0.91) ($0.70) ($0.71) ($0.47) ($0.14) $0.28 $0.04 ($0.40) ($0.37)
Weighted Average Diluted Shares Outstanding		 74.27M 77.14M 77.50M 77.78M 78.89M 88.36M 88.95M 102.62M 89.21M 91.87M 93.48M
Weighted Average Basic & Diluted Shares Outstanding		 76.10M 76.13M 76.49M 78.05M 88.74M 88.80M 89.14M 89.47M 92.24M 92.99M 94.26M

Annual Cash Flow Statements for Travere Therapeutics

This table details how cash moves in and out of Travere Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 20 3.20 58 3.48 -40 22 81 -104 -3.51 1.27 35
Net Cash From Operating Activities		 -1.39 -3.44 7.40 -25 -58 -43 -15 -186 -280 -237 38
Net Cash From Continuing Operating Activities		 -1.39 -3.44 7.40 -25 -58 -43 -76 -261 -325 -230 38
Net Income / (Loss) Continuing Operations		 117 -48 -60 -103 -146 -169 -217 -331 -376 -321 -50
Consolidated Net Income / (Loss)		 117 -48 -60 -103 -146 -169 -180 -278 -111 -322 -26
Net Income / (Loss) Discontinued Operations		 - - - - - - 37 53 265 -0.92 25
Depreciation Expense		 13 16 18 19 20 25 13 21 39 44 61
Amortization Expense		 1.74 1.75 1.99 3.78 9.12 10 13 0.92 -5.74 -2.81 -2.80
Non-Cash Adjustments To Reconcile Net Income		 -121 26 31 53 62 130 34 48 44 113 44
Changes in Operating Assets and Liabilities, net		 -13 0.93 17 2.53 -3.04 -38 81 0.88 -25 -63 -14
Net Cash From Discontinued Operating Activities		 - - - - - - 61 75 45 -7.45 0.00
Net Cash From Investing Activities		 -81 10 46 -203 20 -61 -138 -33 56 99 28
Net Cash From Continuing Investing Activities		 -81 10 46 -203 20 -61 -138 -33 -152 99 28
Acquisitions		 -40 -11 -13 -34 -15 -113 -19 -28 -42 -36 -58
Purchase of Investments		 -199 -184 -102 -331 -224 -215 -547 -385 -444 -126 -237
Sale and/or Maturity of Investments		 9.98 207 162 163 259 273 434 382 335 326 324
Other Investing Activities, net		 0.00 0.00 - - - 0.00 0.00 -0.79 -0.67 -65 -0.40
Net Cash From Discontinued Investing Activities		 - - - - - - 0.00 0.00 207 0.00 0.00
Net Cash From Financing Activities		 102 -3.85 5.45 232 -2.08 128 232 118 219 139 -33
Net Cash From Continuing Financing Activities		 102 -3.85 5.45 232 -2.08 128 238 120 220 139 -33
Repayment of Debt		 -47 -1.36 -0.85 -41 - 0.00 0.00 -221 0.00 0.00 -69
Issuance of Common Equity		 154 6.01 3.65 5.31 1.78 134 227 23 219 137 2.79
Other Financing Activities, net		 4.14 -8.50 1.99 -1.13 -3.85 -5.85 11 2.49 1.14 2.35 33
Net Cash From Discontinued Financing Activities		 - - - - - - -6.10 -2.48 -1.38 0.00 0.00
Other Net Changes in Cash		 - - - - - - - - 1.98 - 2.29
Cash Interest Paid		 5.84 2.07 2.07 1.88 7.67 6.90 7.33 10 8.84 8.84 8.84

Quarterly Cash Flow Statements for Travere Therapeutics

This table details how cash moves in and out of Travere Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -86 -15 -11 4.12 23 3.36 13 36 -18 -15 39
Net Cash From Operating Activities		 -70 -119 -40 -43 -36 -42 4.98 14 61 -40 58
Net Cash From Continuing Operating Activities		 -64 -119 -40 -43 -29 -42 4.98 14 61 -40 58
Net Income / (Loss) Continuing Operations		 -89 -136 -70 -55 -60 -41 -13 26 -22 -37 -35
Consolidated Net Income / (Loss)		 -90 -136 -70 -55 -60 -41 -13 26 2.73 -37 -35
Depreciation Expense		 9.49 9.88 10 11 12 13 14 16 18 25 4.23
Non-Cash Adjustments To Reconcile Net Income		 13 10 80 7.69 15 9.92 9.36 10 15 16 60
Changes in Operating Assets and Liabilities, net		 8.09 -2.95 -61 -6.74 7.40 -24 -5.64 -37 53 -45 28
Net Cash From Investing Activities		 -17 105 29 46 -80 41 4.85 87 -105 22 -206
Net Cash From Continuing Investing Activities		 -18 105 29 46 -80 41 4.85 87 -105 22 -206
Acquisitions		 -5.51 -6.47 -12 -8.19 -9.64 -12 -12 -15 -19 -22 -21
Purchase of Investments		 -63 - - - -126 0.00 - -4.85 -168 -5.06 -222
Sale and/or Maturity of Investments		 50 111 106 54 55 53 81 107 82 49 36
Net Cash From Financing Activities		 0.12 -0.53 0.78 0.05 139 3.72 1.48 -65 27 4.20 188
Net Cash From Continuing Financing Activities		 0.38 -0.53 0.78 0.05 139 3.72 1.48 -65 27 4.20 188
Other Financing Activities, net		 1.58 -0.53 -0.53 0.05 3.36 3.72 -0.06 3.57 25 4.20 27
Other Net Changes in Cash		 - -0.29 - - - 0.55 1.95 0.21 -0.41 -0.06 0.07

Annual Balance Sheets for Travere Therapeutics

This table presents Travere Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 512 525 520 709 605 607 777 673 789 594 605
Total Current Assets		 302 332 326 496 429 410 583 486 617 417 438
Cash & Equivalents		 38 41 99 103 62 85 166 62 58 59 93
Short-Term Investments		 192 215 201 369 336 277 387 389 509 312 230
Accounts Receivable		 12 19 14 13 18 16 16 17 21 27 80
Inventories, net		 2.54 2.83 5.35 5.62 6.08 7.61 7.31 4.52 9.41 6.20 5.88
Prepaid Expenses		 2.38 4.83 3.11 4.14 5.02 8.14 6.72 12 19 13 29
Plant, Property, & Equipment, net		 0.43 2.59 3.23 3.15 2.89 9.42 11 9.05 7.48 5.34 4.02
Total Noncurrent Assets		 210 190 191 210 173 188 183 177 165 172 164
Intangible Assets		 162 182 185 187 157 154 148 97 104 104 114
Other Noncurrent Operating Assets		 1.86 7.36 5.56 7.71 15 33 34 32 60 68 50
Total Liabilities & Shareholders' Equity		 512 525 520 709 605 607 777 673 789 594 605
Total Liabilities		 212 218 227 391 384 396 475 630 588 535 490
Total Current Liabilities		 87 83 86 105 95 93 124 142 178 201 160
Accounts Payable		 7.64 7.52 19 6.95 27 12 15 17 42 24 25
Accrued Expenses		 26 35 38 50 52 57 75 96 119 86 126
Other Current Liabilities		 54 40 29 26 17 6.33 10 10 10 23 9.07
Total Noncurrent Liabilities		 125 134 142 286 288 304 350 488 410 334 330
Long-Term Debt		 44 44 45 195 205 215 227 376 377 310 312
Other Noncurrent Operating Liabilities		 57 83 96 91 83 88 103 37 33 24 19
Commitments & Contingencies		 - - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 300 308 293 318 221 211 302 43 201 59 115
Total Preferred & Common Equity		 300 308 293 318 221 211 302 43 201 59 115
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 300 308 293 318 221 211 302 43 201 59 115
Common Stock		 366 421 472 590 637 798 1,069 1,060 1,328 1,506 1,589
Retained Earnings		 -65 -113 -178 -270 -416 -586 -766 -1,014 -1,126 -1,447 -1,473
Accumulated Other Comprehensive Income / (Loss)		 -0.68 -0.49 -1.02 -1.53 0.73 -0.90 -0.56 -2.91 -1.46 -0.08 -1.19

Quarterly Balance Sheets for Travere Therapeutics

This table presents Travere Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 808 736 833 664 551 504 549 555 539 555 799
Total Current Assets		 605 542 686 481 369 325 374 380 371 393 615
Cash & Equivalents		 161 71 144 43 32 36 62 75 111 78 118
Short-Term Investments		 400 420 490 398 293 241 260 244 144 186 371
Accounts Receivable		 22 20 15 23 24 25 34 39 83 87 81
Inventories, net		 6.71 19 21 4.53 5.98 6.36 3.93 4.09 5.55 6.36 7.84
Prepaid Expenses		 15 12 16 13 13 16 14 17 28 34 37
Plant, Property, & Equipment, net		 9.13 8.57 8.00 6.94 6.58 6.16 4.85 4.56 4.32 3.63 3.23
Total Noncurrent Assets		 194 186 139 176 176 174 170 171 163 159 181
Intangible Assets		 163 154 107 101 105 104 104 106 109 110 132
Other Noncurrent Operating Assets		 31 31 32 74 70 69 66 66 54 49 49
Total Liabilities & Shareholders' Equity		 808 736 833 664 551 504 549 555 539 555 799
Total Liabilities		 619 620 553 589 536 535 516 523 465 456 775
Total Current Liabilities		 131 136 139 173 121 190 182 190 135 125 152
Accounts Payable		 17 20 25 17 26 23 15 19 18 13 7.50
Accrued Expenses		 86 89 96 140 80 84 77 82 106 104 136
Other Current Liabilities		 10 9.90 10 10 10 11 21 20 11 8.12 8.26
Total Noncurrent Liabilities		 488 484 414 416 415 345 334 333 330 331 623
Long-Term Debt		 376 376 377 378 378 310 311 311 311 312 603
Other Noncurrent Operating Liabilities		 104 101 32 38 37 35 23 22 19 19 20
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 189 116 280 74 15 -30 33 33 74 99 25
Total Preferred & Common Equity		 189 116 280 74 15 -30 33 33 74 99 25
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 189 116 280 74 15 -30 33 33 74 99 25
Common Stock		 1,292 1,307 1,319 1,338 1,349 1,357 1,522 1,535 1,550 1,610 1,570
Retained Earnings		 -1,101 -1,186 -1,035 -1,262 -1,332 -1,387 -1,488 -1,501 -1,475 -1,510 -1,545
Accumulated Other Comprehensive Income / (Loss)		 -2.18 -3.86 -3.65 -1.89 -1.63 -1.02 -0.84 -0.81 -1.05 -1.06 -1.12

Annual Metrics And Ratios for Travere Therapeutics

This table displays calculated financial ratios and metrics derived from Travere Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 254.19% 33.74% 15.98% 6.01% 6.75% 13.11% -33.52% -16.97% 32.69% 60.55% 110.45%
EBITDA Growth		 239.81% -129.39% 4.00% -55.35% -86.26% -29.16% -23.99% -71.59% -19.03% 19.04% 102.34%
EBIT Growth		 210.76% -148.42% -0.62% -40.82% -71.00% -26.92% -13.99% -60.06% -21.23% 15.37% 84.34%
NOPAT Growth		 -0.98% 27.76% 7.60% -48.80% -71.62% -28.25% -13.20% -60.37% -21.36% 16.57% 80.60%
Net Income Growth		 205.68% -140.86% -24.69% -71.90% -42.61% -15.71% -6.29% -54.63% 60.00% -188.64% 92.06%
EPS Growth		 171.56% -140.69% -19.38% -64.94% -36.22% -2.89% 15.45% -45.18% 65.68% -172.00% 92.89%
Operating Cash Flow Growth		 96.97% -147.73% 315.14% -437.13% -133.25% 26.58% 65.39% -1,159.40% -50.31% 15.19% 115.91%
Free Cash Flow Firm Growth		 -51.08% 84.89% 191.93% -421.17% -9.92% -139.36% 77.30% -465.40% -28.96% 4.10% 71.58%
Invested Capital Growth		 508.29% -15.61% -60.98% 31.08% -44.11% 199.14% -120.38% 28.64% 193.67% 500.29% 54.02%
Revenue Q/Q Growth		 19.59% 5.43% 3.23% 0.98% 1.69% 38.80% -51.60% 18.56% 84.06% 14.61% 12.60%
EBITDA Q/Q Growth		 7.24% 6.77% 4.77% 11.46% -25.34% -176.17% 11.18% -3.67% 2.57% 9.86% 118.36%
EBIT Q/Q Growth		 10.85% 4.65% 2.44% 6.52% -19.77% -106.47% 14.41% -6.82% 2.99% 8.79% 43.81%
NOPAT Q/Q Growth		 -2.62% -5.47% 5.36% 11.30% -20.30% -28.66% -9.58% -6.95% 2.85% 9.37% 31.06%
Net Income Q/Q Growth		 29.29% -14.69% -17.78% 9.01% -18.45% -117.03% 28.00% -5.39% -27.97% 8.51% 71.15%
EPS Q/Q Growth		 13.21% -98.46% -60.42% 8.63% -17.69% -109.41% 36.63% -5.05% -2.74% 8.11% 72.12%
Operating Cash Flow Q/Q Growth		 79.96% -329.40% 3,236.86% -12.19% -1.62% -28.11% -728.68% -17.51% -5.99% 12.77% 164.46%
Free Cash Flow Firm Q/Q Growth		 -26.93% -37.29% 370.47% -16.76% 7.95% -58.59% 18.25% -10.90% 9.22% 5.36% 34.94%
Invested Capital Q/Q Growth		 14.73% 24.20% -17.51% 21.99% -33.35% 42.50% 16.55% 48.43% -48.89% -4.67% -20.44%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 97.81% 96.59% 97.67% 96.63% 97.01% 96.91% 97.10% 95.96% 92.12% 96.68% 97.89%
EBITDA Margin		 132.64% -29.14% -24.12% -35.35% -61.68% -70.43% -131.37% -271.51% -243.57% -122.83% 1.37%
Operating Margin		 -50.80% -43.58% -34.72% -48.73% -78.34% -88.83% -151.27% -292.17% -267.24% -138.88% -12.80%
EBIT Margin		 117.49% -42.54% -36.90% -49.02% -78.52% -88.11% -151.09% -291.28% -266.15% -140.30% -10.44%
Profit (Net Income) Margin		 117.36% -35.86% -38.55% -62.51% -83.51% -85.43% -136.60% -254.41% -76.70% -137.90% -5.21%
Tax Burden Percent		 111.16% 83.19% 102.34% 100.80% 99.99% 89.75% 83.04% 84.09% 29.62% 100.32% 51.85%
Interest Burden Percent		 89.86% 101.34% 102.08% 126.52% 106.37% 108.04% 108.88% 103.86% 97.30% 97.97% 96.15%
Effective Tax Rate		 -11.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -84.90% -38.73% -56.24% -129.04% -250.42% -224.42% -425.77% 0.00% 0.00% -576.89% -51.40%
ROIC Less NNEP Spread (ROIC-NNEP)		 -352.41% -35.13% -46.79% -111.25% -228.69% -195.82% -407.68% 0.00% 0.00% -472.24% -1,374.98%
Return on Net Nonoperating Assets (RNNOA)		 174.14% 22.96% 36.36% 95.45% 196.13% 146.05% 355.60% 0.00% 0.00% 329.44% 22.02%
Return on Equity (ROE)		 89.25% -15.76% -19.88% -33.59% -54.29% -78.37% -70.17% -161.46% -91.44% -247.45% -29.38%
Cash Return on Invested Capital (CROIC)		 -228.42% -21.79% 31.49% -155.93% -193.83% -324.20% 0.00% 0.00% -2,627.87% -719.77% -93.93%
Operating Return on Assets (OROA)		 36.24% -10.95% -10.94% -13.10% -20.96% -28.83% -28.78% -44.00% -52.90% -47.31% -8.55%
Return on Assets (ROA)		 36.20% -9.23% -11.42% -16.70% -22.29% -27.95% -26.02% -38.43% -15.24% -46.50% -4.26%
Return on Common Equity (ROCE)		 89.25% -15.76% -19.88% -33.59% -54.29% -78.37% -70.17% -161.46% -91.44% -247.45% -29.38%
Return on Equity Simple (ROE_SIMPLE)		 39.08% -15.56% -20.38% -32.26% -66.20% -80.22% -59.61% -649.88% -55.47% -544.28% 0.00%
Net Operating Profit after Tax (NOPAT)		 -56 -41 -38 -56 -96 -123 -140 -224 -272 -227 -44
NOPAT Margin		 -56.47% -30.50% -24.30% -34.11% -54.84% -62.18% -105.89% -204.52% -187.07% -97.21% -8.96%
Net Nonoperating Expense Percent (NNEP)		 267.51% -3.60% -9.45% -17.79% -21.73% -28.60% -18.09% -29.23% 131.17% -104.65% 1,323.58%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -53.51% -47.00% -51.75% -10.31%
Cost of Revenue to Revenue		 2.19% 3.41% 2.33% 3.37% 2.99% 3.09% 2.90% 4.04% 7.88% 3.32% 2.11%
SG&A Expenses to Revenue		 79.63% 68.82% 65.40% 63.11% 73.54% 68.47% 95.79% 180.45% 182.83% 113.27% 68.71%
R&D to Revenue		 50.48% 53.01% 50.45% 75.35% 80.40% 115.42% 152.58% 207.69% 168.68% 121.24% 41.98%
Operating Expenses to Revenue		 148.62% 140.17% 132.39% 145.37% 175.36% 185.74% 248.37% 388.14% 359.36% 235.56% 110.70%
Earnings before Interest and Taxes (EBIT)		 117 -57 -57 -81 -138 -175 -199 -319 -387 -327 -51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 132 -39 -37 -58 -108 -140 -173 -297 -354 -286 6.70
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.32 2.32 2.83 2.93 2.76 6.59 6.29 31.49 3.36 23.01 29.77
Price to Tangible Book Value (P/TBV)		 5.07 5.72 7.71 7.15 9.67 24.37 12.37 0.00 7.01 0.00 3,561.19
Price to Revenue (P/Rev)		 6.98 5.35 5.35 5.68 3.48 7.02 14.42 12.33 4.65 5.83 6.97
Price to Earnings (P/E)		 5.95 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 16.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 4.48 5.22 15.24 13.49 15.12 15.33 0.00 0.00 43.31 20.31 32.84
Enterprise Value to Revenue (EV/Rev)		 5.12 3.76 3.70 4.05 2.37 6.37 12.00 11.65 3.35 5.87 6.94
Enterprise Value to EBITDA (EV/EBITDA)		 3.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 508.53
Enterprise Value to EBIT (EV/EBIT)		 4.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 77.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 90.19
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 27.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.15 0.14 0.15 0.68 0.93 1.10 0.77 8.76 1.88 6.42 2.71
Long-Term Debt to Equity		 0.15 0.14 0.15 0.61 0.93 1.02 0.75 8.76 1.88 5.25 2.71
Financial Leverage		 -0.49 -0.65 -0.78 -0.86 -0.86 -0.75 -0.87 -1.08 -1.00 -0.70 -0.02
Leverage Ratio		 2.47 1.71 1.74 2.01 2.44 2.80 2.70 4.20 6.00 5.32 6.90
Compound Leverage Factor		 2.22 1.73 1.78 2.54 2.59 3.03 2.94 4.36 5.84 5.21 6.63
Debt to Total Capital		 12.73% 12.61% 13.33% 40.60% 48.08% 52.42% 43.65% 89.76% 65.26% 86.51% 73.08%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 4.19% 0.00% 3.92% 1.38% 0.00% 0.00% 15.68% 0.00%
Long-Term Debt to Total Capital		 12.73% 12.61% 13.33% 36.41% 48.08% 48.51% 42.27% 89.76% 65.26% 70.84% 73.08%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 87.27% 87.39% 86.67% 59.40% 51.92% 47.58% 56.35% 10.24% 34.74% 13.49% 26.92%
Debt to EBITDA		 0.33 -1.14 -1.21 -3.75 -1.89 -1.67 -1.35 -1.26 -1.07 -1.32 46.52
Net Debt to EBITDA		 -1.40 5.43 6.84 4.63 1.79 0.92 1.84 0.25 0.54 -0.03 -1.65
Long-Term Debt to EBITDA		 0.33 -1.14 -1.21 -3.36 -1.89 -1.54 -1.31 -1.26 -1.07 -1.08 46.52
Debt to NOPAT		 -0.78 -1.09 -1.20 -3.88 -2.13 -1.89 -1.68 -1.68 -1.39 -1.67 -7.09
Net Debt to NOPAT		 3.29 5.19 6.79 4.80 2.01 1.04 2.28 0.33 0.70 -0.04 0.25
Long-Term Debt to NOPAT		 -0.78 -1.09 -1.20 -3.48 -2.13 -1.75 -1.62 -1.68 -1.39 -1.37 -7.09
Altman Z-Score		 3.25 2.14 2.20 1.42 0.19 0.76 1.05 -1.61 -2.07 -2.87 1.86
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.47 3.99 3.80 4.74 4.50 4.43 4.70 3.42 3.47 2.08 2.74
Quick Ratio		 3.32 3.86 3.67 4.63 4.36 4.07 4.58 3.28 3.31 1.98 2.52
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -152 -23 21 -68 -74 -178 -40 -229 -295 -283 -80
Operating Cash Flow to CapEx		 0.00% -240.97% 834.61% -3,433.01% -29,853.33% -631.64% -289.98% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -36.57 -31.63 4.77 -2.52 0.00 0.00 0.00 -12.30 -26.02 -25.29 -7.48
Operating Cash Flow to Interest Expense		 -0.33 -4.75 1.67 -0.93 0.00 0.00 0.00 -10.02 -24.71 -21.24 3.52
Operating Cash Flow Less CapEx to Interest Expense		 35.41 -6.72 1.47 -0.96 0.00 0.00 0.00 -10.02 -24.71 -21.24 3.52
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.31 0.26 0.30 0.27 0.27 0.33 0.19 0.15 0.20 0.34 0.82
Accounts Receivable Turnover		 9.78 8.63 9.57 12.38 11.42 11.68 8.28 6.72 7.68 9.66 9.15
Inventory Turnover		 1.31 1.70 0.88 1.01 0.89 0.90 0.51 0.75 1.64 0.99 1.71
Fixed Asset Turnover		 181.79 88.62 53.27 51.52 58.09 32.22 12.85 10.86 17.57 36.39 104.88
Accounts Payable Turnover		 0.30 0.60 0.27 0.43 0.31 0.32 0.28 0.27 0.39 0.24 0.43
Days Sales Outstanding (DSO)		 37.30 42.31 38.14 29.48 31.96 31.26 44.07 54.29 47.53 37.80 39.89
Days Inventory Outstanding (DIO)		 278.72 214.88 413.95 362.23 407.99 407.84 713.22 488.70 222.08 367.88 213.14
Days Payable Outstanding (DPO)		 1,233.07 607.57 1,339.51 854.95 1,170.45 1,154.31 1,303.84 1,339.19 939.84 1,536.76 853.17
Cash Conversion Cycle (CCC)		 -917.04 -350.39 -887.42 -463.24 -730.50 -715.21 -546.54 -796.20 -670.23 -1,131.08 -600.14
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 114 96 38 49 28 82 -17 -12 11 67 104
Invested Capital Turnover		 1.50 1.27 2.31 3.78 4.57 3.61 4.02 -7.61 -382.71 5.93 5.74
Increase / (Decrease) in Invested Capital		 95 -18 -59 12 -22 55 -99 4.81 23 56 36
Enterprise Value (EV)		 511 503 573 664 416 1,263 1,582 1,275 486 1,368 3,408
Market Capitalization		 697 714 828 933 610 1,391 1,900 1,350 676 1,360 3,419
Book Value per Share		 $8.30 $8.16 $7.46 $7.72 $5.15 $4.14 $4.93 $0.67 $2.67 $0.76 $1.28
Tangible Book Value per Share		 $3.80 $3.31 $2.73 $3.17 $1.47 $1.12 $2.51 ($0.84) $1.28 ($0.58) $0.01
Total Capital		 344 352 338 536 426 444 536 418 578 438 427
Total Debt		 44 44 45 218 205 233 234 376 377 379 312
Total Long-Term Debt		 44 44 45 195 205 215 227 376 377 310 312
Net Debt		 -186 -211 -256 -269 -194 -129 -319 -75 -190 8.29 -11
Capital Expenditures (CapEx)		 -148 1.43 0.89 0.73 0.20 6.77 5.10 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -15 -6.78 -60 -58 -65 -26 -87 -106 -128 -86 -45
Debt-free Net Working Capital (DFNWC)		 215 249 240 414 334 335 466 344 439 285 278
Net Working Capital (NWC)		 215 249 240 391 334 318 459 344 439 216 278
Net Nonoperating Expense (NNE)		 -174 7.15 22 47 50 46 40 55 -160 95 -18
Net Nonoperating Obligations (NNO)		 -186 -211 -256 -269 -194 -129 -319 -55 -190 8.29 -11
Total Depreciation and Amortization (D&A)		 15 18 20 22 30 35 26 22 33 41 58
Debt-free, Cash-free Net Working Capital to Revenue		 -14.67% -5.08% -39.04% -35.33% -37.02% -13.33% -65.80% -96.81% -88.12% -36.91% -9.20%
Debt-free Net Working Capital to Revenue		 215.18% 186.46% 154.99% 251.77% 190.27% 168.99% 353.57% 314.52% 302.17% 122.07% 56.58%
Net Working Capital to Revenue		 215.18% 186.46% 154.99% 238.09% 190.27% 160.22% 347.96% 314.52% 302.17% 92.61% 56.58%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $3.49 ($1.29) ($1.54) ($2.54) ($3.46) ($3.56) ($3.01) ($4.37) ($1.50) ($4.08) ($0.29)
Adjusted Weighted Average Basic Shares Outstanding		 33.56M 37.00M 38.77M 40.43M 43.12M 60.24M 59.83M 63.76M 74.27M 78.89M 89.21M
Adjusted Diluted Earnings per Share		 $3.17 ($1.29) ($1.54) ($2.54) ($3.46) ($3.56) ($3.01) ($4.37) ($1.50) ($4.08) ($0.29)
Adjusted Weighted Average Diluted Shares Outstanding		 37.58M 38.29M 38.77M 40.43M 43.12M 60.24M 59.83M 63.76M 74.27M 78.89M 89.21M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.54) ($3.46) ($3.56) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 36.51M 38.09M 39.69M 41.41M 42.34M 47.54M 63.21M 64.74M 76.10M 88.74M 92.24M
Normalized Net Operating Profit after Tax (NOPAT)		 -23 -24 -33 -56 -68 -123 -140 -224 -264 -225 -44
Normalized NOPAT Margin		 -22.61% -17.67% -21.49% -34.22% -38.67% -62.18% -105.89% -204.52% -181.58% -96.48% -8.96%
Pre Tax Income Margin		 105.58% -43.10% -37.67% -62.02% -83.52% -95.19% -164.51% -302.54% -258.96% -137.45% -10.04%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 28.27 -78.38 -12.93 -3.00 0.00 0.00 0.00 -17.15 -34.10 -29.26 -4.77
NOPAT to Interest Expense		 -13.59 -56.21 -8.52 -2.09 0.00 0.00 0.00 -12.04 -23.97 -20.27 -4.09
EBIT Less CapEx to Interest Expense		 64.02 -80.35 -13.13 -3.03 0.00 0.00 0.00 -17.15 -34.10 -29.26 -4.77
NOPAT Less CapEx to Interest Expense		 22.16 -58.18 -8.72 -2.11 0.00 0.00 0.00 -12.04 -23.97 -20.27 -4.09
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 8.10% 0.00% 0.00% -8.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Travere Therapeutics

This table displays calculated financial ratios and metrics derived from Travere Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 92,241,550.00 92,992,905.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 92,241,550.00 92,992,905.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -0.40 -0.37
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 311.85% 33.95% 68.08% 69.56% 65.98% 97.54% 111.49% 162.11% 73.41% 55.63% 48.17%
EBITDA Growth		 14.79% -42.42% 34.71% 45.04% 40.96% 77.29% 101.38% 192.83% 93.45% 59.78% 854.64%
EBIT Growth		 11.36% -42.88% 31.64% 39.70% 33.97% 69.69% 81.49% 145.69% 65.16% 12.15% 128.73%
NOPAT Growth		 10.79% -43.00% 34.87% 39.35% 35.55% 69.35% 81.32% 163.41% 46.60% 13.50% 131.26%
Net Income Growth		 -36.99% -57.60% 17.78% -136.36% 33.17% 69.70% 81.88% 146.90% 104.53% 10.00% -172.81%
EPS Growth		 -3.88% -38.58% 19.47% -135.53% 33.64% 73.30% 84.62% 140.00% 105.63% 14.89% -164.29%
Operating Cash Flow Growth		 -28.98% -46.71% 41.93% 28.12% 49.31% 64.54% 112.38% 133.68% 269.87% 4.33% 1,065.38%
Free Cash Flow Firm Growth		 -13.23% -6.09% -11.63% 19.99% -10.65% -11.74% 68.13% 60.44% 40.10% 24.90% -24.24%
Invested Capital Growth		 193.67% 2.09% 703.17% 221.84% 500.29% 739.57% 37.11% 84.54% 54.02% 62.36% 48.42%
Revenue Q/Q Growth		 21.47% -8.18% 30.80% 16.23% 18.90% 9.29% 40.03% 44.05% -21.33% -1.92% 33.32%
EBITDA Q/Q Growth		 -3.22% -53.84% 52.87% 27.05% -10.90% 40.43% 102.86% 4,805.48% -107.83% -265.59% 167.99%
EBIT Q/Q Growth		 -0.66% -49.69% 48.78% 21.87% -10.23% 31.30% 68.72% 292.91% -184.05% -73.22% 110.23%
NOPAT Q/Q Growth		 -1.78% -47.76% 51.38% 17.07% -8.17% 29.74% 70.36% 381.46% -191.09% -13.83% 110.71%
Net Income Q/Q Growth		 -159.82% -50.89% 48.25% 22.15% -9.95% 31.59% 69.06% 301.54% -89.38% -1,459.55% 6.21%
EPS Q/Q Growth		 -154.31% -64.49% 48.30% 23.08% -1.43% 33.80% 70.21% 300.00% -85.71% -1,100.00% 7.50%
Operating Cash Flow Q/Q Growth		 -19.18% -68.87% 66.18% -5.63% 15.97% -18.12% 111.81% 187.32% 323.82% -166.52% 243.86%
Free Cash Flow Firm Q/Q Growth		 18.94% -9.55% -9.35% 17.61% -12.10% -10.64% 68.81% -2.28% -69.72% -38.71% 48.40%
Invested Capital Q/Q Growth		 -48.89% -4.47% 533.17% 4.11% -4.67% 33.61% 3.40% 40.12% -20.44% 40.84% -5.48%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 89.87% 96.36% 96.19% 97.41% 96.59% 94.28% 98.67% 99.04% 98.03% 98.47% 98.72%
EBITDA Margin		 -185.03% -312.08% -112.45% -70.57% -65.82% -35.88% 0.73% 24.99% -2.49% -9.27% 4.73%
Operating Margin		 -209.13% -336.53% -125.11% -89.27% -81.21% -52.21% -11.05% 15.12% -25.01% -29.02% 2.33%
EBIT Margin		 -206.09% -335.96% -131.57% -88.44% -81.99% -51.54% -11.51% 15.42% -16.47% -29.09% 2.23%
Profit (Net Income) Margin		 -200.12% -328.86% -130.11% -87.14% -80.58% -50.44% -11.14% 15.59% 2.10% -29.17% -20.52%
Tax Burden Percent		 101.86% 100.22% 101.21% 99.95% 99.87% 100.09% 100.16% 99.97% -12.96% 101.03% 99.42%
Interest Burden Percent		 95.33% 97.67% 97.71% 98.57% 98.41% 97.77% 96.65% 101.16% 98.61% 99.23% -924.73%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.03% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -3,457.36% -407.65% -274.53% -337.36% -198.51% -32.10% 65.54% -100.40% -92.26% 8.35%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -3,425.46% -324.42% -254.73% -317.78% 169.42% -39.00% 66.53% -1,926.66% -113.80% -34.85%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 3,149.29% 136.30% 160.10% 221.69% -9.78% -92.05% 243.77% 30.85% -90.47% -105.83%
Return on Equity (ROE)		 -91.44% -308.07% -271.35% -114.43% -115.67% -208.29% -124.16% 309.31% -69.54% -182.73% -97.48%
Cash Return on Invested Capital (CROIC)		 -2,627.87% -2,838.92% -877.95% -645.30% -719.77% -473.32% -181.10% -122.88% -93.93% -81.37% -63.48%
Operating Return on Assets (OROA)		 -40.96% -71.09% -36.30% -26.91% -27.65% -23.26% -6.95% 12.89% -13.48% -28.26% 1.95%
Return on Assets (ROA)		 -39.77% -69.59% -35.90% -26.52% -27.17% -22.76% -6.73% 13.03% 1.72% -28.33% -17.91%
Return on Common Equity (ROCE)		 -91.44% -308.07% -271.35% -114.43% -115.67% -208.29% -124.16% 309.31% -69.54% -182.73% -97.48%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -217.53% -963.28% 1,154.05% 0.00% -690.70% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -66 -97 -47 -39 -43 -30 -8.86 25 -23 -26 2.77
NOPAT Margin		 -146.39% -235.57% -87.58% -62.49% -56.85% -36.55% -7.74% 15.12% -17.50% -20.32% 1.63%
Net Nonoperating Expense Percent (NNEP)		 -19.81% -31.90% -83.23% -19.79% -19.58% -367.93% 6.90% -0.99% 1,826.26% 21.54% 43.20%
Return On Investment Capital (ROIC_SIMPLE)		 -11.41% - - - -9.71% -7.25% -2.15% 6.47% -5.32% -6.29% 0.44%
Cost of Revenue to Revenue		 10.13% 3.64% 3.81% 2.59% 3.41% 5.72% 1.33% 0.96% 1.97% 1.53% 1.28%
SG&A Expenses to Revenue		 141.12% 155.23% 119.70% 104.33% 92.93% 89.12% 66.59% 52.44% 78.42% 63.09% 56.68%
R&D to Revenue		 132.60% 277.05% 100.40% 82.16% 82.99% 57.37% 43.13% 31.48% 44.62% 44.89% 35.55%
Operating Expenses to Revenue		 299.00% 432.90% 221.30% 186.68% 177.80% 146.49% 109.72% 83.92% 123.04% 127.49% 96.39%
Earnings before Interest and Taxes (EBIT)		 -93 -139 -71 -56 -61 -42 -13 25 -21 -37 3.79
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -83 -129 -61 -44 -49 -29 0.84 41 -3.23 -12 8.02
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.36 7.82 41.31 0.00 23.01 48.45 40.14 28.96 29.77 27.76 215.44
Price to Tangible Book Value (P/TBV)		 7.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3,561.19 0.00 0.00
Price to Revenue (P/Rev)		 4.65 3.72 3.52 5.26 5.83 5.81 3.94 4.89 6.97 5.11 8.93
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 43.31 48.14 10.00 16.57 20.31 18.30 14.77 16.77 32.84 19.08 39.07
Enterprise Value to Revenue (EV/Rev)		 3.35 3.31 3.82 5.76 5.87 6.02 4.12 5.02 6.94 5.20 9.13
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 508.53 103.16 157.77
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 90.19 70.38 58.22
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.88 5.10 24.96 -12.43 6.42 11.56 11.60 4.23 2.71 3.16 24.58
Long-Term Debt to Equity		 1.88 5.10 24.96 -10.18 5.25 9.46 9.50 4.23 2.71 3.16 24.58
Financial Leverage		 -1.00 -0.92 -0.42 -0.63 -0.70 -0.06 2.36 3.66 -0.02 0.80 3.04
Leverage Ratio		 6.00 5.59 9.78 5.36 5.32 11.34 23.10 24.19 6.90 8.39 23.65
Compound Leverage Factor		 5.72 5.46 9.56 5.29 5.24 11.09 22.33 24.48 6.80 8.33 -218.74
Debt to Total Capital		 65.26% 83.60% 96.15% 108.75% 86.51% 92.04% 92.06% 80.89% 73.08% 75.97% 96.09%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 19.71% 15.68% 16.68% 16.68% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 65.26% 83.60% 96.15% 89.04% 70.84% 75.36% 75.38% 80.89% 73.08% 75.97% 96.09%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 34.74% 16.40% 3.85% -8.75% 13.49% 7.96% 7.94% 19.11% 26.92% 24.03% 3.91%
Debt to EBITDA		 -1.07 -0.98 -1.07 -1.19 -1.32 -2.06 -3.11 -8.53 46.52 11.55 17.62
Net Debt to EBITDA		 0.54 0.16 -0.15 -0.32 -0.03 -0.31 -0.49 -1.56 -1.65 1.75 3.32
Long-Term Debt to EBITDA		 -1.07 -0.98 -1.07 -0.98 -1.08 -1.69 -2.55 -8.53 46.52 11.55 17.62
Debt to NOPAT		 -1.39 -1.25 -1.37 -1.51 -1.67 -2.39 -3.15 -4.88 -7.09 -7.81 -21.28
Net Debt to NOPAT		 0.70 0.21 -0.19 -0.40 -0.04 -0.36 -0.50 -0.89 0.25 -1.19 -4.01
Long-Term Debt to NOPAT		 -1.39 -1.25 -1.37 -1.24 -1.37 -1.95 -2.58 -4.88 -7.09 -7.81 -21.28
Altman Z-Score		 -0.85 -1.97 -2.25 -2.29 -1.40 -1.28 -1.34 0.40 2.02 1.12 2.84
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.47 2.78 3.04 1.71 2.08 2.05 2.00 2.75 2.74 3.13 4.05
Quick Ratio		 3.31 2.68 2.89 1.59 1.98 1.95 1.89 2.50 2.52 2.81 3.75
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -89 -98 -107 -88 -99 -109 -34 -35 -59 -82 -42
Operating Cash Flow to CapEx		 0.00% 0.00% -49,076.83% 0.00% 0.00% 0.00% 0.00% 10,226.43% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -38.31 -31.69 0.00 -38.21 -11.96 -12.66 -25.76 -35.64 -1.00
Operating Cash Flow to Interest Expense		 0.00 0.00 -14.43 -15.31 0.00 -14.77 1.75 5.20 26.45 -17.55 1.38
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -14.46 -15.31 0.00 -14.77 1.75 5.15 26.45 -17.55 1.38
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.20 0.21 0.28 0.30 0.34 0.45 0.60 0.84 0.82 0.97 0.87
Accounts Receivable Turnover		 7.68 7.04 7.92 10.24 9.66 9.58 10.57 8.06 9.15 8.81 9.91
Inventory Turnover		 1.64 1.57 0.76 0.72 0.99 2.58 2.06 1.74 1.71 1.48 1.39
Fixed Asset Turnover		 17.57 19.38 23.45 28.74 36.39 46.38 59.93 83.16 104.88 126.46 151.78
Accounts Payable Turnover		 0.39 0.53 0.41 0.41 0.24 0.68 0.46 0.50 0.43 0.54 0.62
Days Sales Outstanding (DSO)		 47.53 51.88 46.09 35.65 37.80 38.10 34.54 45.29 39.89 41.42 36.84
Days Inventory Outstanding (DIO)		 222.08 232.95 479.43 507.54 367.88 141.47 177.00 210.15 213.14 246.72 263.38
Days Payable Outstanding (DPO)		 939.84 693.04 886.69 896.71 1,536.76 536.50 790.86 731.20 853.17 678.34 588.14
Cash Conversion Cycle (CCC)		 -670.23 -408.21 -361.17 -353.52 -1,131.08 -356.93 -579.32 -475.77 -600.14 -390.20 -287.92
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 11 11 68 71 67 90 93 130 104 146 138
Invested Capital Turnover		 -382.71 14.68 4.65 4.39 5.93 5.43 4.15 4.34 5.74 4.54 5.12
Increase / (Decrease) in Invested Capital		 23 0.22 59 49 56 79 25 60 36 56 45
Enterprise Value (EV)		 486 516 679 1,171 1,368 1,647 1,375 2,187 3,408 2,788 5,397
Market Capitalization		 676 579 626 1,070 1,360 1,590 1,314 2,130 3,419 2,740 5,283
Book Value per Share		 $2.67 $0.96 $0.20 ($0.40) $0.76 $0.37 $0.37 $0.83 $1.28 $1.07 $0.26
Tangible Book Value per Share		 $1.28 ($0.35) ($1.18) ($1.76) ($0.58) ($0.80) ($0.82) ($0.40) $0.01 ($0.12) ($1.15)
Total Capital		 578 452 393 348 438 412 413 385 427 411 627
Total Debt		 377 378 378 379 379 379 380 311 312 312 603
Total Long-Term Debt		 377 378 378 310 310 311 311 311 312 312 603
Net Debt		 -190 -63 53 101 8.29 57 60 57 -11 47 114
Capital Expenditures (CapEx)		 0.00 0.00 0.08 0.00 0.00 0.00 0.00 0.14 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -128 -133 -78 -74 -86 -62 -61 -18 -45 2.57 -26
Debt-free Net Working Capital (DFNWC)		 439 308 248 203 285 260 259 236 278 267 463
Net Working Capital (NWC)		 439 308 248 135 216 192 190 236 278 267 463
Net Nonoperating Expense (NNE)		 24 39 23 16 18 11 3.90 -0.78 -25 11 38
Net Nonoperating Obligations (NNO)		 -190 -63 53 101 8.29 57 60 57 -11 47 114
Total Depreciation and Amortization (D&A)		 9.49 9.88 10 11 12 13 14 16 18 25 4.23
Debt-free, Cash-free Net Working Capital to Revenue		 -88.12% -85.53% -43.73% -36.44% -36.91% -22.58% -18.17% -4.24% -9.20% 0.48% -4.41%
Debt-free Net Working Capital to Revenue		 302.17% 197.69% 139.44% 99.93% 122.07% 95.23% 77.54% 54.16% 56.58% 49.84% 78.32%
Net Working Capital to Revenue		 302.17% 197.69% 139.44% 66.21% 92.61% 70.09% 56.92% 54.16% 56.58% 49.84% 78.32%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.07) ($1.76) ($0.91) ($0.70) ($0.71) ($0.47) ($0.14) $0.29 $0.03 ($0.40) ($0.37)
Adjusted Weighted Average Basic Shares Outstanding		 74.27M 77.14M 77.50M 77.78M 78.89M 88.36M 88.95M 89.23M 89.21M 91.87M 93.48M
Adjusted Diluted Earnings per Share		 ($1.07) ($1.76) ($0.91) ($0.70) ($0.71) ($0.47) ($0.14) $0.28 $0.04 ($0.40) ($0.37)
Adjusted Weighted Average Diluted Shares Outstanding		 74.27M 77.14M 77.50M 77.78M 78.89M 88.36M 88.95M 102.62M 89.21M 91.87M 93.48M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 76.10M 76.13M 76.49M 78.05M 88.74M 88.80M 89.14M 89.47M 92.24M 92.99M 94.26M
Normalized Net Operating Profit after Tax (NOPAT)		 -58 -97 -47 -39 -42 -30 -8.86 25 -23 -26 2.77
Normalized NOPAT Margin		 -128.69% -235.13% -86.73% -62.35% -55.54% -36.55% -7.74% 15.12% -17.50% -20.32% 1.63%
Pre Tax Income Margin		 -196.47% -328.15% -128.55% -87.18% -80.68% -50.39% -11.13% 15.60% -16.24% -28.87% -20.64%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -25.54 -20.03 0.00 -14.74 -4.63 9.24 -9.31 -16.09 0.09
NOPAT to Interest Expense		 0.00 0.00 -17.00 -14.15 0.00 -10.46 -3.11 9.06 -9.90 -11.24 0.07
EBIT Less CapEx to Interest Expense		 0.00 0.00 -25.57 -20.03 0.00 -14.74 -4.63 9.19 -9.31 -16.09 0.09
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -17.03 -14.15 0.00 -10.46 -3.11 9.01 -9.90 -11.24 0.07
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Travere Therapeutics (NASDAQ:TVTX) is showing meaningful improvement in revenue and operating performance, but the latest quarter also introduced a sharp increase in debt and interest expense. The company remains dependent on product revenue growth, cost control and balance-sheet management to reach sustainable profitability.

  • Revenue growth remains strong. Second-quarter 2026 revenue was $169.6 million, up approximately 48% from $114.4 million in the second quarter of 2025 and more than double the $74.8 million reported in the fourth quarter of 2024.
  • Gross margins are very high. Gross profit was $167.4 million in Q2 2026, representing a gross margin of approximately 98.7%. The cost of revenue was only $2.2 million, leaving substantial revenue available to fund research, selling and administrative expenses.
  • Operating performance improved sequentially. Travere produced operating income of $4.0 million in Q2 2026, compared with an operating loss of $36.9 million in Q1 2026. This marks a significant improvement and suggests that rising revenue is beginning to absorb the company’s fixed operating costs.
  • Operating cash flow rebounded. Cash flow from operations improved to $58.1 million in Q2 2026 from an outflow of $40.4 million in Q1 2026. The latest quarter was also considerably stronger than the $5.0 million generated in Q2 2025, although quarterly cash flow has been volatile.
  • Near-term liquidity is substantial. Cash and short-term investments totaled approximately $489.2 million at June 30, 2026, compared with $152.0 million of current liabilities. This provides a sizeable liquidity cushion for operating expenses, research programs and near-term obligations.
  • Investment balances are being actively managed. Travere purchased $221.6 million of investments and sold or matured $36.4 million during Q2 2026, contributing to a $206.3 million investing cash outflow. These transactions appear to reflect treasury management rather than a deterioration in operations, but they make quarter-to-quarter cash trends harder to interpret.
  • Interest expense surged in the latest quarter. Interest expense increased to $42.1 million in Q2 2026 from $2.3 million in Q1 2026 and $2.8 million in Q2 2025. As a result, the company’s $4.0 million operating profit became a $35.0 million pretax loss and a $34.8 million net loss.
  • Debt increased sharply. Long-term debt rose to $602.8 million at the end of Q2 2026 from approximately $312.1 million in Q1 2026. Total debt now exceeds cash and short-term investments by roughly $113.6 million, reversing the company’s previously stronger net liquidity position.
  • Travere remains unprofitable on a bottom-line basis. The company reported a net loss in Q2 2026, Q1 2026, Q4 2025 and Q2 2025. Retained earnings were negative $1.54 billion, highlighting the cumulative impact of years of losses.
  • Share dilution and limited equity provide additional risks. Weighted-average basic shares increased to 93.5 million in Q2 2026 from 88.9 million in Q2 2025. Total shareholders’ equity also fell to $24.5 million from $98.7 million in Q1 2026, leaving the company with a relatively thin equity cushion compared with its $774.8 million of total liabilities.

Overall, the income statement is moving in a more favorable direction: revenue is expanding rapidly, gross margins remain excellent and operating income turned positive in Q2 2026. However, the sharp rise in debt and interest expense is currently preventing that operating improvement from translating into net profitability. Investors should closely monitor whether operating cash flow remains positive and whether Travere can reduce leverage or sustain enough earnings growth to service its larger debt burden.

09/03/26 06:04 PM ETAI Generated. May Contain Errors.

Travere Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Travere Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Travere Therapeutics' net income appears to be on an upward trend, with a most recent value of -$25.55 million in 2025, falling from $117.24 million in 2015. The previous period was -$321.55 million in 2024. View Travere Therapeutics' forecast to see where analysts expect Travere Therapeutics to go next.

Travere Therapeutics' total operating income in 2025 was -$62.82 million, based on the following breakdown:
  • Total Gross Profit: $480.39 million
  • Total Operating Expenses: $543.21 million

Over the last 10 years, Travere Therapeutics' total revenue changed from $99.89 million in 2015 to $490.73 million in 2025, a change of 391.3%.

Travere Therapeutics' total liabilities were at $490.36 million at the end of 2025, a 8.4% decrease from 2024, and a 131.0% increase since 2015.

In the past 10 years, Travere Therapeutics' cash and equivalents has ranged from $37.81 million in 2015 to $165.75 million in 2021, and is currently $93.04 million as of their latest financial filing in 2025.

Over the last 10 years, Travere Therapeutics' book value per share changed from 8.30 in 2015 to 1.28 in 2025, a change of -84.5%.


Related Companies

Financial statements for NASDAQ:TVTX last updated on 8/4/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel